Abstract
In order to overcome the significant side effects and the acquired resistance of platinum-based anticancer drugs, great efforts have been devoted to designing new platinum compounds or non-platinum transition metal anticancer complexes with improved pharmacological properties and a broader range of antitumor activity. Among them, the new complexes based on natural alkaloid and their derivatives provide a novel approach to potential (pro-)drugs. This review was mainly focused on the recent progresses of alkaloid-metal based anticancer agents, including metal complexes of natural or synthetic alkaloids, liriodenine, β-carboline, and quinolinoline as anticancer agents, their in vitro anticancer activities and primary action mechanism. Additionally, the future development of hybrid alkaloid and its derivatives metal complexes as anticancer drugs was discussed, which might hold a promise for overcoming multidrug resistance (MDR).
Keywords: Alkaloid, liriodenine, β-carboline alkaloid, quinolinoline, anticancer agents, metal complexes.
Current Topics in Medicinal Chemistry
Title:Alkaloid-Metal Based Anticancer Agents
Volume: 13 Issue: 17
Author(s): Zhen-Feng Chen, Yan-Cheng Liu, Ke-Bin Huang and Hong Liang
Affiliation:
Keywords: Alkaloid, liriodenine, β-carboline alkaloid, quinolinoline, anticancer agents, metal complexes.
Abstract: In order to overcome the significant side effects and the acquired resistance of platinum-based anticancer drugs, great efforts have been devoted to designing new platinum compounds or non-platinum transition metal anticancer complexes with improved pharmacological properties and a broader range of antitumor activity. Among them, the new complexes based on natural alkaloid and their derivatives provide a novel approach to potential (pro-)drugs. This review was mainly focused on the recent progresses of alkaloid-metal based anticancer agents, including metal complexes of natural or synthetic alkaloids, liriodenine, β-carboline, and quinolinoline as anticancer agents, their in vitro anticancer activities and primary action mechanism. Additionally, the future development of hybrid alkaloid and its derivatives metal complexes as anticancer drugs was discussed, which might hold a promise for overcoming multidrug resistance (MDR).
Export Options
About this article
Cite this article as:
Chen Zhen-Feng, Liu Yan-Cheng, Huang Ke-Bin and Liang Hong, Alkaloid-Metal Based Anticancer Agents, Current Topics in Medicinal Chemistry 2013; 13 (17) . https://dx.doi.org/10.2174/15680266113139990146
DOI https://dx.doi.org/10.2174/15680266113139990146 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Human Microdialysis
Current Pharmaceutical Biotechnology Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Application of Transcranial Color-Coded Duplex Sonography in Stroke Diagnosis
Current Medical Imaging Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets